Medacta Group (LTS:0A05) Other Current Liabilities: CHF56.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A05 Medacta Group SA LTS:0A05
83 GF Score
Price CHF116.71
GF Value CHF165.58
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medacta Group Other Current Liabilities?

Medacta Group LTS:0A05 -1.09% 83 Other Current Liabilities is CHF56.4 Mil as of Jun. 2026. GuruFocus rates LTS:0A05 with a GF Score™ of 83/100 and a GF Value™ of CHF165.58 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Medacta Group's other current liabilities for the quarter that ended in Jun. 2026 was CHF56.4 Mil.

Medacta Group's quarterly other current liabilities declined from Jun. 2025 (CHF114.1 Mil) to Dec. 2025 (CHF51.3 Mil) but then increased from Dec. 2025 (CHF51.3 Mil) to Jun. 2026 (CHF56.4 Mil).

Medacta Group's annual other current liabilities increased from Dec. 2023 (CHF45.4 Mil) to Dec. 2024 (CHF49.8 Mil) and increased from Dec. 2024 (CHF49.8 Mil) to Dec. 2025 (CHF51.3 Mil).

Medacta Group Other Current Liabilities Related Terms

Medacta Group Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Medacta Group's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group Other Current Liabilities Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.67 37.68 45.36 49.81 51.32

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.11 49.81 114.10 51.32 56.44
LTS:0A05
83GF Score
Medacta Group SA LTS:0A05
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of CHF56.4 Mil mean?
Medacta Group (LTS:0A05) has a Other Current Liabilities of CHF56.4 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medacta Group.
Is Medacta Group's Other Current Liabilities too high?
Medacta Group's current Other Current Liabilities is CHF56.4 Mil. Overall, Medacta Group has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Other Current Liabilities compare to ABT and SYK?
Medacta Group's Other Current Liabilities of CHF56.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medacta Group. Medacta Group's current Other Current Liabilities is CHF56.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (LTS:0A05) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF165.58, compared to a current price of CHF116.71 — trading 29.5% below its estimated fair value. The current Other Current Liabilities is CHF56.4 Mil. Medacta Group's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Medacta Group (LTS:0A05), the current Other Current Liabilities is CHF56.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (LTS:0A05) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of CHF116.71 is trading 29.5% below its estimated GF Value™ of CHF165.58. GuruFocus considers Medacta Group to be Significantly Undervalued.

Key valuation signals for LTS:0A05:

  • Other Current Liabilities: CHF56.4 Mil
  • GF Value™: CHF165.58 vs. price of CHF116.71 (29.5% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the LTS:0A05 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
83GF Score

Get the complete analysis for LTS:0A05

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF116.71
Price
CHF165.58
GF Value